Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole

References

• Groll AH, Walsh TJ. Potential new antifungal agents. Curr Opin Infect Dis 1997;10:449–58
   Web of Science ®Google Scholar
• Andriole VT. Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 1999;44:151–62
   PubMed Web of Science ®Google Scholar
• Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hemato-logic malignancies. Blood 2003;101:3365–72
   PubMed Web of Science ®Google Scholar
• Calandra T. Candida infections in the intensive care unit. Curr Opin Crit Care 1997;3:335–41
   Google Scholar
• Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999;78:123–38
   PubMed Web of Science ®Google Scholar
• Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001;21:1107–14
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNuble MJ, Reboli A, Bow E, Lister J, Anaissie EJ. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383–96
   PubMed Web of Science ®Google Scholar
• Arathoon EG. Clinical efficacy of echinocandin antifungals Curr Opin Infect Dis 2001;14:685–91
   PubMed Web of Science ®Google Scholar
• Edwards JE Jr. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997;25:43–59
   PubMed Web of Science ®Google Scholar
• Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000;5:120–35
   PubMedGoogle Scholar
• Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract 2001;55:633–8
   PubMed Web of Science ®Google Scholar
• Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis KA, Lupinacci R, Smietana JM, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294–9
   PubMed Web of Science ®Google Scholar
• Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. A randomized, double-blind, multicenter study of caspofungin versus amphotericin B for the treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002;46:451–7
   PubMed Web of Science ®Google Scholar
• Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529–35
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotsteain C, Lopes-Columbo A, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;247:2020–9
   Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, M, Selleslag D, Petersen FB, Sable CA, Kartsonis N, Ngai A, Taylor A, Patterson TF,, Denning D, Walsh T. Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungals: an analysis of 90 patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27–30, 2002; San Diego, CA. Poster M–868
   Google Scholar
• Cancidas™ [package insert]. Whitehouse Station, NJ: Merck & Co., Inc; 2001
   Google Scholar
• Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: an echinocandin antifungal agent. Clin Ther 2002;24:351–77
   PubMed Web of Science ®Google Scholar
• Ally R, Shurmann D, Kreisel, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ and the Esophageal Candidiasis Study Group. A randomized, double-blind, double-dummy multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447–54
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563–71
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Lee J for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225–34
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, Bennette JE, Greene RE, Oestmann J-W, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconzole versus amphotericin B for primary therapy. N Engl J Med 2002;347:408–15
   PubMed Web of Science ®Google Scholar
• Sable C, Nguyen B-Y T, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002;4:25–30
   PubMedGoogle Scholar
• Trenschel R, Trampenaue C, Elmaagacil A, Ditschkowski M, Ottinger H, Peceny R, Muller K-D, Rath PM, Dermourmi H, Beelen DW, Schaefer UW. Caspofungin (CSF) after allogeneic stem cell transplantation (SCT): a single center experience of 16 patients (pts) treated for fever of unknown origin (FUO) or invasive mycosis (IM). 28th Annual Meeting of the European Group for Blood and Marrow Transplantation. Montreux, Switzerland, March 26, 2002. Abstract
   Google Scholar
• Caspofungin acetate. FDA Advisory Committee Meeting Background. December 6, 2000. www.fda.gov/ohrms/dockets/ac/01/briefing/3676B1.htm
   Google Scholar
• VFEND™ [package insert]. New York, NY: Pfizer Inc., 2002
   Google Scholar
• FDA Antiviral Drugs Advisory Committee, 4 October 2001. Briefing document for voriconazole. Pfizer. (Accessed February 5, 2001 at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.PDF)
   Google Scholar
• Walsh, TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Miller A, Sable CA, Kartsonis NA, Stone JA. Pharmacokinetics (PK) of caspofungin (CAS) in pediatric patients. 42nd International Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 27–30 September, 2002. M-896 (Abstract)
   Google Scholar
• Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240–8
   PubMed Web of Science ®Google Scholar
• Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692–6
   PubMed Web of Science ®Google Scholar
• Lomaestro BM. Caspofungin. An echinocandin antifungal for the treatment of invasive aspergillosis. Formulary 2001;36:427–36
   Web of Science ®Google Scholar